drugset / Trial / NCT03688152

A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma

NCT03688152

Phase 1 Completed 9 enrolled Incyte Corporation
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of INCB053914 in combination with INCB050465 in relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Timeline

Start
2018-12-03
Primary completion
2020-09-01
Completion
2020-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject INCB053914 Unknown
Subject Parsaclisib Small molecule